These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36466843)

  • 1. Combined impact of the inter and intra-patient variability of tacrolimus blood level on allograft outcomes in kidney transplantation.
    Park Y; Lee H; Eum SH; Ko EJ; Min JW; Yoon SH; Hwang WM; Yun SR; Yang CW; Shin J; Chung BH
    Front Immunol; 2022; 13():1037566. PubMed ID: 36466843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
    Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
    Front Immunol; 2021; 12():746013. PubMed ID: 34659243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation.
    Xie W; Fan S; Liu R; Yan W; Su C; Zheng K; Wang X; Wang Z
    Transplant Rev (Orlando); 2024 Jul; 38(3):100842. PubMed ID: 38537484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection.
    Sablik KA; Clahsen-van Groningen MC; Hesselink DA; van Gelder T; Betjes MGH
    PLoS One; 2018; 13(5):e0196552. PubMed ID: 29746495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience.
    Du W; Wang X; Zhang D; Zuo X
    Eur J Clin Pharmacol; 2024 May; 80(5):747-757. PubMed ID: 38363388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors.
    Larpparisuth N; Pongnatcha T; Panprom P; Promraj R; Premasathian N; Vongwiwatana A
    Ther Drug Monit; 2021 Oct; 43(5):624-629. PubMed ID: 33278239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
    Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
    Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
    Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes.
    Mendoza Rojas A; Hesselink DA; van Besouw NM; Dieterich M; de Kuiper R; Baan CC; van Gelder T
    Ther Drug Monit; 2022 Jun; 44(3):369-376. PubMed ID: 35394988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
    Kim EJ; Kim SJ; Huh KH; Kim BS; Kim MS; Kim SI; Kim YS; Lee J
    Sci Rep; 2021 Jun; 11(1):12114. PubMed ID: 34108576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes.
    Defrancq C; De Wilde N; Raes A; Van Biervliet S; Vande Velde S; Van Winckel M; De Bruyne R; Prytuła A
    Pediatr Transplant; 2019 May; 23(3):e13388. PubMed ID: 30916883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients.
    Taber DJ; Hirsch J; Keys A; Su Z; McGillicuddy JW
    Ther Drug Monit; 2021 Jun; 43(3):401-407. PubMed ID: 33560095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide.
    Marco DN; Salas MQ; Gutiérrez-García G; Monge I; Riu G; Carcelero E; Roma JR; Llobet N; Arcarons J; Suárez-Lledó M; Martínez N; Pedraza A; Domenech A; Rosiñol L; Fernández-Avilés F; Urbano-Ispízua Á; Rovira M; Brunet M; Martínez C
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High intra-patient variability of tacrolimus within post-operative 1 month predicted worse 1-year outcomes in pediatric liver transplant recipients.
    Chen F; Yong JK; Shen C; Zhou T; Feng M; Wan P; Luo Y; Lin H; Qian Y; Xia Q
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1017-1027. PubMed ID: 38502358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus Concentration-to-Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes.
    Bartlett FE; Carthon CE; Hagopian JC; Horwedel TA; January SE; Malone A
    Pharmacotherapy; 2019 Aug; 39(8):827-836. PubMed ID: 31230376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.
    Baghai Arassi M; Gauche L; Schmidt J; Höcker B; Rieger S; Süsal C; Tönshoff B; Fichtner A
    Pediatr Nephrol; 2022 Oct; 37(10):2503-2514. PubMed ID: 35166920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation.
    Choi JS; Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Kang HG; Ha IS; Min S
    Pediatr Transplant; 2022 Sep; 26(6):e14297. PubMed ID: 35466485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.
    Shuker N; van Gelder T; Hesselink DA
    Transplant Rev (Orlando); 2015 Apr; 29(2):78-84. PubMed ID: 25687818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.